Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028
**Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。